CY1109624T1 - Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις - Google Patents
Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησειςInfo
- Publication number
- CY1109624T1 CY1109624T1 CY20091101192T CY091101192T CY1109624T1 CY 1109624 T1 CY1109624 T1 CY 1109624T1 CY 20091101192 T CY20091101192 T CY 20091101192T CY 091101192 T CY091101192 T CY 091101192T CY 1109624 T1 CY1109624 T1 CY 1109624T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparations
- compounds
- receptor antagonists
- therapeutic uses
- substituted thiophene
- Prior art date
Links
- 229920002527 Glycogen Polymers 0.000 title 1
- 229940096919 glycogen Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003577 thiophenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65249205P | 2005-02-11 | 2005-02-11 | |
| EP06720513A EP1856090B1 (en) | 2005-02-11 | 2006-02-09 | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109624T1 true CY1109624T1 (el) | 2014-08-13 |
Family
ID=36694345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101192T CY1109624T1 (el) | 2005-02-11 | 2009-11-12 | Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8084489B2 (enExample) |
| EP (1) | EP1856090B1 (enExample) |
| JP (1) | JP4988604B2 (enExample) |
| KR (1) | KR20070104409A (enExample) |
| CN (1) | CN101115735B (enExample) |
| AT (1) | ATE445609T1 (enExample) |
| AU (1) | AU2006213894B2 (enExample) |
| BR (1) | BRPI0607015A2 (enExample) |
| CA (1) | CA2597073C (enExample) |
| CR (1) | CR9304A (enExample) |
| CY (1) | CY1109624T1 (enExample) |
| DE (1) | DE602006009773D1 (enExample) |
| DK (1) | DK1856090T3 (enExample) |
| EA (1) | EA200701705A1 (enExample) |
| ES (1) | ES2332470T3 (enExample) |
| IL (1) | IL184932A0 (enExample) |
| MA (1) | MA29432B1 (enExample) |
| MX (1) | MX2007009661A (enExample) |
| NO (1) | NO20074567L (enExample) |
| PL (1) | PL1856090T3 (enExample) |
| PT (1) | PT1856090E (enExample) |
| SI (1) | SI1856090T1 (enExample) |
| TN (1) | TNSN07313A1 (enExample) |
| WO (1) | WO2006086488A2 (enExample) |
| ZA (1) | ZA200706354B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455756T1 (de) * | 2004-06-14 | 2010-02-15 | Lilly Co Eli | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung |
| PT2129654E (pt) | 2007-02-09 | 2014-09-04 | Metabasis Therapeutics Inc | Antagonistas do receptor de glucagina |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2011001708A (es) | 2008-08-13 | 2011-04-26 | Metabasis Therapeutics Inc | Antagonistas de glucagon. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012085745A1 (en) | 2010-12-23 | 2012-06-28 | Pfizer Inc. | Glucagon receptor modulators |
| PT2673260T (pt) | 2011-02-08 | 2016-10-24 | Pfizer | Modulador do recetor de glucagon |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| JP5647379B2 (ja) | 2011-07-22 | 2014-12-24 | ファイザー・インク | キノリニルグルカゴン受容体モジュレーター |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| US9649294B2 (en) | 2013-11-04 | 2017-05-16 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2017519000A (ja) | 2014-06-12 | 2017-07-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴンアンタゴニスト |
| EP3350200A4 (en) | 2015-09-18 | 2019-03-27 | Wake Forest University Health Services | ANGIOTENSIN (1 7) ANALOGUE AND ASSOCIATED PROCEDURES |
| US20180289859A1 (en) | 2015-10-05 | 2018-10-11 | Hettwer Holding Aps | Compositions and methods for treatment of bone defects |
| CA2914601A1 (en) * | 2015-12-11 | 2017-06-11 | Wake Forest University Health Sciences | Angiotensin-(1-7) analogs and methods relating thereto |
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP7781519B2 (ja) | 2017-08-22 | 2025-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| JP2021513564A (ja) | 2018-02-13 | 2021-05-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体拮抗薬 |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1463715A1 (en) * | 2001-12-03 | 2004-10-06 | Novo Nordisk A/S | Novel glucagon antagonists |
| AU2003233780A1 (en) * | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| WO2005118542A1 (en) * | 2004-05-28 | 2005-12-15 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| ATE455756T1 (de) | 2004-06-14 | 2010-02-15 | Lilly Co Eli | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung |
-
2006
- 2006-02-09 US US11/815,987 patent/US8084489B2/en not_active Expired - Fee Related
- 2006-02-09 ES ES06720513T patent/ES2332470T3/es not_active Expired - Lifetime
- 2006-02-09 AT AT06720513T patent/ATE445609T1/de active
- 2006-02-09 AU AU2006213894A patent/AU2006213894B2/en not_active Ceased
- 2006-02-09 BR BRPI0607015-9A patent/BRPI0607015A2/pt not_active IP Right Cessation
- 2006-02-09 PL PL06720513T patent/PL1856090T3/pl unknown
- 2006-02-09 CN CN2006800046189A patent/CN101115735B/zh not_active Expired - Fee Related
- 2006-02-09 SI SI200630534T patent/SI1856090T1/sl unknown
- 2006-02-09 JP JP2007555195A patent/JP4988604B2/ja not_active Expired - Fee Related
- 2006-02-09 MX MX2007009661A patent/MX2007009661A/es active IP Right Grant
- 2006-02-09 PT PT06720513T patent/PT1856090E/pt unknown
- 2006-02-09 DK DK06720513T patent/DK1856090T3/da active
- 2006-02-09 CA CA2597073A patent/CA2597073C/en not_active Expired - Fee Related
- 2006-02-09 EP EP06720513A patent/EP1856090B1/en not_active Expired - Lifetime
- 2006-02-09 KR KR1020077018437A patent/KR20070104409A/ko not_active Ceased
- 2006-02-09 EA EA200701705A patent/EA200701705A1/ru unknown
- 2006-02-09 DE DE602006009773T patent/DE602006009773D1/de not_active Expired - Lifetime
- 2006-02-09 WO PCT/US2006/004461 patent/WO2006086488A2/en not_active Ceased
-
2007
- 2007-07-30 IL IL184932A patent/IL184932A0/en unknown
- 2007-07-31 ZA ZA200706354A patent/ZA200706354B/xx unknown
- 2007-08-10 CR CR9304A patent/CR9304A/es not_active Application Discontinuation
- 2007-08-10 TN TNP2007000313A patent/TNSN07313A1/en unknown
- 2007-09-10 NO NO20074567A patent/NO20074567L/no not_active Application Discontinuation
- 2007-09-11 MA MA30221A patent/MA29432B1/fr unknown
-
2009
- 2009-11-12 CY CY20091101192T patent/CY1109624T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1856090T3 (da) | 2009-11-30 |
| SI1856090T1 (sl) | 2010-02-26 |
| DE602006009773D1 (de) | 2009-11-26 |
| ATE445609T1 (de) | 2009-10-15 |
| CA2597073A1 (en) | 2006-08-17 |
| NO20074567L (no) | 2007-11-08 |
| CR9304A (es) | 2008-03-31 |
| PT1856090E (pt) | 2009-11-18 |
| TNSN07313A1 (en) | 2008-12-31 |
| IL184932A0 (en) | 2007-12-03 |
| EA200701705A1 (ru) | 2008-02-28 |
| KR20070104409A (ko) | 2007-10-25 |
| CN101115735B (zh) | 2013-01-09 |
| CA2597073C (en) | 2014-11-25 |
| ZA200706354B (en) | 2008-11-26 |
| WO2006086488A3 (en) | 2006-12-14 |
| AU2006213894A1 (en) | 2006-08-17 |
| US20100137417A1 (en) | 2010-06-03 |
| US8084489B2 (en) | 2011-12-27 |
| BRPI0607015A2 (pt) | 2009-12-01 |
| ES2332470T3 (es) | 2010-02-05 |
| AU2006213894B2 (en) | 2011-12-08 |
| JP4988604B2 (ja) | 2012-08-01 |
| MA29432B1 (fr) | 2008-05-02 |
| MX2007009661A (es) | 2007-09-25 |
| CN101115735A (zh) | 2008-01-30 |
| EP1856090A2 (en) | 2007-11-21 |
| JP2008530102A (ja) | 2008-08-07 |
| EP1856090B1 (en) | 2009-10-14 |
| WO2006086488A2 (en) | 2006-08-17 |
| PL1856090T3 (pl) | 2010-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109624T1 (el) | Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| WO2007106181A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| WO2007120270A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |